The American Nurses Credentialing Center (ANCC) hosted a Standards for Commercial Support Users Group meeting on February 21. The meeting followed up on discussions the participants held in August about the role of accreditors in supporting data collection for the Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategy (REMS) for long-acting and extended-release opioids. Murray Kopelow, MD, ACCME Chief Executive; and Kate Regnier, MA, MBA, ACCME Deputy Chief Executive and COO, represented the ACCME. In addition to the ACCME and ANCC, participating organizations included the Accreditation Council for Pharmacy Education, the American Academy of Family Physicians, the American Academy of Physician Assistants, the Association of Regulatory Boards of Optometry, and the Food and Drug Administration.
The Standards for Commercial Support Users Group Meetings bring together leadership from accrediting organizations to discuss strategies for ensuring the independence of continuing education in health care and related fields.
FDA information about the opioid REMS, including links to the FDA draft blueprint, letter to manufacturers, and frequently asked questions, is available here. The ACCME comment in support of the blueprint is available here. Previously, the ACCME issued a news release, Q&A, and an audio commentary by Dr. Kopelow regarding the role of accredited CME in the REMS for opioid medications. In May 2011, continuing health care education leadership organizations issued a joint news release to express their support for the opioid REMS.